LEAWOOD, Kan., April 5, 2018 /PRNewswire/ -- Aratana
Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company
focused on the licensing, development and commercialization of
innovative therapeutics for dogs and cats, confirmed that it has
received a notice of nomination of three director candidates for
election to the Company's Board of Directors at the 2018 Annual
Meeting of Stockholders from Engaged Capital, LLC and certain of
its affiliated entities, which earlier today filed a Schedule 13D
disclosing ownership of 5.2% of Aratana's outstanding shares.
Aratana stockholders are not required to take any action at this
time. Members of Aratana's Board and management have recently held
discussions with representatives of Engaged Capital and those
discussions are ongoing. Aratana's Board intends to review the
qualifications and experience of the nominees and present its
formal recommendation regarding director nominations in the
Company's proxy materials that will be filed with the Securities
and Exchange Commission.
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative therapeutics for dogs and cats. Aratana
believes that it can leverage the investment in the human
biopharmaceutical industry to bring therapeutics to dogs and cats
in a capital and time efficient manner. The company's pipeline
includes therapeutic candidates for the potential treatment of
pain, inappetence, viral diseases, allergy, cancer and other
serious medical conditions. Aratana believes the development and
commercialization of these therapeutics will permit veterinarians
and pet owners to manage pets' medical needs safely and
effectively, resulting in longer and improved quality of life for
pets. For more information, please visit www.aratana.com.
Forward-Looking Statements Disclaimer
This press
release includes statements that may constitute forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including, but
not limited to, expectations regarding Aratana's anticipated review
of Engaged Capital's director nominees, the accuracy of which are
necessarily subject to risks, uncertainties, and assumptions as to
future events that may not prove to be accurate. These statements
are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond the Company's
control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. Existing
and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. Important factors that could cause actual results to
differ materially from those expressed or implied include the fact
that Aratana may choose not to consider Engaged Capital's nominees,
and the other factors discussed in the Company's most recent Annual
Report on Form 10-K and other filings with the SEC. The Company
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as may be required under applicable securities
law.
Important Stockholder Information and Where You Can Find
It
Aratana plans to file with the SEC and mail to its
stockholders a definitive proxy statement and accompanying
definitive WHITE proxy card in connection with the Company's 2018
Annual Meeting of Stockholders. The definitive proxy statement will
contain important information about Aratana, the 2018 Annual
Meeting of Stockholders and related matters. INVESTORS AND
STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, THE
ACCOMPANYING WHITE PROXY CARD AND ANY OTHER RELEVANT SOLICITATION
MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS WILL
CONTAIN IMPORTANT INFORMATION.
Aratana, its directors and certain of its executive officers may
be deemed to be participants in the solicitation of proxies from
the Company's stockholders in connection with the matters to be
considered at the Aratana 2018 Annual Meeting of Stockholders.
Information regarding the names of the Company's directors and
executive officers and their respective interests in Aratana will
be set forth in the definitive proxy statement, the accompanying
definitive WHITE proxy card and other relevant solicitation
materials and in Form 3s and Form 4s filed by the Company's
directors and executive officers after the date of the definitive
proxy statement. These documents (when they become available), and
any and all documents filed by Aratana with the SEC, may be
obtained by investors and stockholders free of charge on the SEC's
website at www.sec.gov. Copies will also be available at no charge
on the Company's website at www.aratana.com.
Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026
MacKenzie Partners, Inc.
Laurie Connell
212-378-7071
lconnell@mackenziepartners.com
Dan Burch
212-929-5748
dburch@mackenziepartners.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-confirms-receipt-of-board-nominations-300625019.html
SOURCE Aratana Therapeutics